trial | Page 72 of 77 | Health Newstrack

Cholesterol lowering drug may fight staph infection

Cholesterol lowering drug could offer a new direction for therapies against staph infection – a bacterium that’s becoming increasingly resistant to antibiotics. – An international team of researchers supported by the National Institutes of Health (NIH) has blocked staph infections in mice using a drug previously tested in clinical trials as a cholesterol-lowering agent. The novel approach, described in the February 14 online edition of Science, could offer a new direction for therapies against a bacterium that’s becoming increasingly resistant to antibiotics.

Oxcarbazepine doesn’t help prevent migraine after all

Researchers found no difference between the oxcarbazepine and placebo groups in the change in the number of migraine attacks from the beginning to the end of the study. – Contrary to some reports, the epilepsy drug oxcarbazepine does not appear to prevent migraine, according to research published in the February 12, 2008, issue of Neurology, the medical journal of the American Academy of Neurology.

New MS drug rituximab shows promise for multiple sclerosis

Genentech Inc. and Biogen Idec Inc.’s cancer drug Rituxan (rituximab) reduced brain lesions in multiple sclerosis patients. – A drug therapy, using rituximab, dramatically reduced the number of inflammatory lesions that form along nerve fibers in brains of multiple sclerosis patients, revealed by researchers recently.

Part of ACCORD study halted due to safety concerns

Canadian Diabetes Association has issued its position statement regarding safety concerns of diabetes treatment in ACCORD study. It is important that people with diabetes not make any changes to their treatments or adjust their blood glucose targets without speaking to their healthcare team. – Canadian Diabetes Association has issued its position statement regarding safety concerns of diabetes treatment in ACCORD study – “It is important that people with diabetes not make any changes to their treatments or adjust their blood glucose targets without speaking to their healthcare team”.

DCIS patients overestimate breast cancer risks

Many women diagnosed with ductal carcinoma in situ (DCIS) have inaccurate perceptions of their breast cancer risks, according to a study published online February 12 in the Journal of the National Cancer Institute. – Many women with newly diagnosed DCIS have inaccurate perceptions of the breast cancer risks that they face, and anxiety is particularly associated with these inaccurate perceptions.

Avastin found effective in advanced breast cancer patients

Avado Study of Avastin Plus Docetaxel Chemotherapy Showed Improved Progression-Free Survival in Patients With Advanced Breast Cancer – Genentech, Inc. (NYSE: DNA) announced that AVADO, a Roche-sponsored Phase III, placebo-controlled study evaluating Avastin? (bevacizumab) in combination with docetaxel chemotherapy met its primary endpoint of prolonging progression-free survival (PFS) in patients who had not received prior chemotherapy for their locally recurrent or metastatic HER2-negative breast cancer.

Most with high blood pressure do not follow DASH diet

The dietary profile of adults with HTN (Hypertension) in the United States has a low accordance with the (Dietary Approaches to Stop Hypertension) DASH dietary pattern, and the dietary quality of adults with HTN has deteriorated since the introduction of the DASH diet, suggesting that secular trends have minimized the impact of the DASH message. – A relatively small proportion of individuals with hypertension (high blood pressure) eat diets that align with government guidelines for controlling the disease, according to a report in the February 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Breast cancer sufferers demand answers from PHARMAC, New Zealand

Herceptin Heroines are back in the High Court today to continue their case against drug funding agency PHARMAC, New Zealand. – 8 cancer survivors are in the New Zealand High Court to fight their case against drug funding agency PHARMAC. The women are challenging PHARMAC’s decision not to fund 12 months of Herceptin treatment for NZ women with HER2 positive breast cancer.

New hope for hepatitis C sufferers

Adelaide scientists will lead a $2 million five-year project to develop new vaccines and explore better treatment options for hepatitis C sufferers. – University of Adelaide virologists Dr Michael Beard and Dr Karla Helbig will work with colleagues from the University of NSW to develop new strategies to treat and prevent hepatitis C, which infects more than 170 million people around the world.

$9 million grant for prostate cancer research

$9 million grant from the National Cancer Institute (NCI) awarded to Henry Ford to study the effectiveness of gene therapy to treat prostate cancer. – Henry Ford Hospital is embarking on an expanded major clinical trial involving the use of gene therapy in combination with radiation therapy, to determine if the combined treatment is more effective than radiation therapy alone for patients with intermediate risk prostate cancer.